What is Gilead Sciences's livdelzi — total revenues?

Gilead Sciences (GILD) reported livdelzi — total revenues of $167M in Q2 2026.

What does livdelzi — total revenues mean?

This metric represents the total net sales generated from the commercialization of Livdelzi, a therapeutic product focused on the treatment of liver diseases. It captures the revenue contribution from this specific asset within the company's broader portfolio of specialized liver disease treatments. Monitoring this figure provides insight into the market adoption, pricing power, and competitive positioning of this specific therapeutic within the hepatology market.

Gilead Sciences (GILD) Livdelzi — Total revenues

Screener

Other product segments

Biktarvy

$3.77B+6.9%

Descovy

$967M+48.1%

Trodelvy

$457M+25.5%

Yescarta

$346M-12.0%

Sofosbuvir/Velpatasvir

$303M-11.4%

Genvoya

$289M-23.3%

Vemlidy

$289M+14.7%

Odefsey

$239M-19.8%

Yeztugo

$232M+1,447%

Royalty, contract and other revenues

$176M+552%

Symtuza - Revenue share

$138M+11.3%

Other Liver Disease

$118M-4.1%

AmBisome

$110M-14.7%

Tecartus

$70M-23.9%

Other HIV

$56M-39.1%

Other

$51M-30.1%

Veklury

$23M-81.0%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$7.8B+10.2%

Gross profit$6.2B+11.5%

Operating income-$10.4B-520%

Net income-$10.5B-636%

EPS (diluted)-$8.45-642%

Balance sheet

See full

Cash & equivalents$3.2B-38.2%

Total debt$26.2B+5.2%

Total equity$11.8B-39.9%

Total assets$49.4B-11.4%

Cash flow

See full

Operating cash flow$3.6B+332%

CapEx$140.0M+30.8%

Free cash flow$3.4B+377%

Valuation

See full

Market cap$163.59B+19.3%

Enterprise value$186.66B+18.9%

P/S5.4×+0.6×

Profitability

See full

Gross margin79.6%+1.1pp

Operating margin-8.2%-36.1pp

Net margin-10.6%-32.5pp

FCF margin42.5%+10.0pp

Returns & leverage

See full

Return on equity-20.6%-53.8pp

Debt / equity2.2×+1.0×

Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:13 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000882095-26-000031

(in millions)	Three Months Ended June 30, 2026 / U.S.	Three Months Ended June 30, 2026 / Europe	Three Months Ended June 30, 2026 / Rest of World	Three Months Ended June 30, 2026 / Total	Three Months Ended June 30, 2025 / U.S.	Three Months Ended June 30, 2025 / Europe	Three Months Ended June 30, 2025 / Rest of World	Three Months Ended June 30, 2025 / Total
Other HIV(2)	23	24	10	56	50	33	9	92
Total HIV	4,659	640	393	5,693	4,096	624	368	5,088
Liver Disease
Livdelzi	147	20	—	167	74	4	—	78
Sofosbuvir/Velpatasvir(3)	142	81	80	303	184	81	76	342
Vemlidy	124	13	152	289	122	13	117	252
Other Liver Disease(4)	20	79	19	118	33	72	19	123
Total Liver Disease	433	193	251	877	413	170	211	795

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's livdelzi — total revenues?: Gilead Sciences (GILD) reported livdelzi — total revenues of $167M in Q2 2026.
What does livdelzi — total revenues mean?: This metric represents the total net sales generated from the commercialization of Livdelzi, a therapeutic product focused on the treatment of liver diseases. It captures the revenue contribution from this specific asset within the company's broader portfolio of specialized liver disease treatments. Monitoring this figure provides insight into the market adoption, pricing power, and competitive positioning of this specific therapeutic within the hepatology market.